Oophorectomy improves pituitary activin inhibitory function preventing lactotroph hyperplasia development

in Endocrine-Related Cancer
View More View Less
  • 1 Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina
  • | 2 Centro de Microscopia Electrónica, Instituto de Investigaciones en Ciencias de la Salud (INICSA-CONICET), Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina

Correspondence should be addressed to G Díaz-Torga: gdiaz@ibyme.conicet.gov.ar

*(M Peña-Zanoni and E Y Faraoni contributed equally to this work)

Restricted access

Among pituitary adenomas, prolactinomas are the most frequently diagnosed (about 50%). Dopamine agonists are generally effective in the treatment of prolactinomas. However, a subset of about 25% of patients does not respond to these agents. The management of drug-resistant prolactinomas remains a challenge for endocrinologists and new inhibitory treatments are needed. Pituitary activins inhibit lactotroph function. Its expression and action were found reduced in animal models of lactotroph hyperplasia (female mice overexpressing the B subunit of the human chorionic gonadotrophin and female mice knockout for dopamine receptor type 2). In these models, an oophorectomy avoids prolactinoma development. Hormonal replacement with oestradiol and/or progesterone is not enough to reach the tumor size observed in transgenic females. We postulated that the loss of gonadal inhibins after an oophorectomy contributes to prevent hyperplasia development. Here, we demonstrated that an oophorectomy at 2 months age recovers the following in adulthood: (i) pituitary activin expression, (ii) activin receptor expression specifically in lactotroph population, (iii) activin biological activity in lactotrophs with a concomitant reduction of Pit-1 expression. To summarize, when an oophorectomy is performed, inhibins are lost and the inhibitory action of pituitary activins on lactotroph population is recovered, helping to prevent lactotroph hyperplasia development. These results emphasize the importance of the inhibitory action of activins on lactotroph function, positioning activins as a good therapeutic target for the treatment of resistant prolactinomas.

 

Society for Endocrinology logo

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 194 194 194
Full Text Views 2 2 2
PDF Downloads 4 4 4
  • Ahtiainen P, Sharp V, Rulli SB, Rivero-Muller A, Mamaeva V, Roytta M & Huhtaniemi I 2010 Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocrine-Related Cancer 17 611621. (https://doi.org/10.1677/ERC-10-0016)

    • Search Google Scholar
    • Export Citation
  • Asa SL, Kelly MA, Grandy DK & Low MJ 1999 Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140 53485355. (https://doi.org/10.1210/endo.140.11.7118)

    • Search Google Scholar
    • Export Citation
  • Banskota S & Adamson DC 2021 Pituitary adenomas: from diagnosis to therapeutics. Biomedicines 9 494. (https://doi.org/10.3390/biomedicines9050494)

    • Search Google Scholar
    • Export Citation
  • Bilezikjian LM, Blount AL, Leal AMO, Donaldson CJ, Fischer WH & Vale WW 2004 Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Molecular and Cellular Endocrinology 225 2936. (https://doi.org/10.1016/j.mce.2004.02.010)

    • Search Google Scholar
    • Export Citation
  • Bilezikjian LM, Justice NJ, Blackler AN, Wiater E & Vale WW 2012 Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin. Molecular and Cellular Endocrinology 359 4352. (https://doi.org/10.1016/j.mce.2012.01.025)

    • Search Google Scholar
    • Export Citation
  • Ciccarelli A, Daly AF & Beckers A 2005 The epidemiology of prolactinomas. Pituitary 8 36. (https://doi.org/10.1007/s11102-005-5079-0)

  • Colao A & Savastano S 2011 Medical treatment of prolactinomas. Nature Reviews: Endocrinology 7 267278. (https://doi.org/10.1038/nrendo.2011.37)

    • Search Google Scholar
    • Export Citation
  • Dalkin AC, Haisenleder DJ, Yasin M, Gilrain JT & Marshall JC 1996 Pituitary activin receptor subtypes and follistatin gene expression in female rats: differential regulation by activin and follistatin. Endocrinology 137 548554. (https://doi.org/10.1210/endo.137.2.8593801)

    • Search Google Scholar
    • Export Citation
  • Daly AF & Beckers A 2020 The epidemiology of pituitary adenomas. Endocrinology and Metabolism Clinics of North America 49 347355. (https://doi.org/10.1016/j.ecl.2020.04.002)

    • Search Google Scholar
    • Export Citation
  • De Guise C, Lacerte A, Rafiei S, Reynaud R, Roy M, Brue T & Lebrun JJ 2006 Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a smad-independent manner. Endocrinology 147 43514362. (https://doi.org/10.1210/en.2006-0444)

    • Search Google Scholar
    • Export Citation
  • Díaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, Rubinstein M & Becú-Villalobos D 2002 Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 143 12701279. (https://doi.org/10.1210/endo.143.4.8750)

    • Search Google Scholar
    • Export Citation
  • Faraoni EY, Camilletti MA, Abeledo-Machado A, Ratner LD, de Fino F, Ipo Huhtaniemi I, Rulli SB & Díaz-Torga G 2017 Sex differences in the development of prolactinoma in mice overexpressing hCGB: role of TGFB1. Journal of Endocrinology 232 535546. (https://doi.org/10.1530/JOE-16-0371)

    • Search Google Scholar
    • Export Citation
  • Faraoni EY, Abeledo Machado AI, Pérez PA, Marcial López CA, Camilletti MA, Peña-Zanoni M, Rulli SB, Gutiérrez S & Díaz-Torga G 2020 Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia. Journal of Endocrinology 244 415429. (https://doi.org/10.1530/JOE-19-0326)

    • Search Google Scholar
    • Export Citation
  • Fortin J, Ongaro L, Li Y, Tran S, Lamba P, Wang Y, Zhou X & Bernard DJ 2015 Minireview: Activin signaling in gonadotropes: what does the FOX say... to the SMAD? Molecular Endocrinology 29 963977. (https://doi.org/10.1210/me.2015-1004)

    • Search Google Scholar
    • Export Citation
  • Freeman ME, Kanyicska B, Lerant A & Nagy G 2000 Prolactin: structure, function, and regulation of secretion. Physiological Reviews 80 15231631. (https://doi.org/10.1152/physrev.2000.80.4.1523)

    • Search Google Scholar
    • Export Citation
  • Grattan DR 2015 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis. Journal of Endocrinology 226 T101T122. (https://doi.org/10.1530/JOE-15-0213)

    • Search Google Scholar
    • Export Citation
  • Heinzlmann A, Koves K & Nagy GM 2010 Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities. Endocrine 37 396402. (https://doi.org/10.1007/s12020-010-9320-x)

    • Search Google Scholar
    • Export Citation
  • Hentges ST & Low MJ 2002 Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice. Endocrinology 143 45364543. (https://doi.org/10.1210/en.2002-220421)

    • Search Google Scholar
    • Export Citation
  • Kars M, Dekkers OM, Pereira AM & Romijn JA 2010 Update in prolactinomas. Netherlands Journal of Medicine 68 104112.

  • Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N & Grandy DK et al.1997 Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19 103113. (https://doi.org/10.1016/s0896-6273(0080351-7)

    • Search Google Scholar
    • Export Citation
  • Keogh EJ, Lee VW, Rennie GC, Burger HG, Hudson B & De Kretser DM 1976 Selective suppression of FSH by testicular extracts. Endocrinology 98 9971004. (https://doi.org/10.1210/endo-98-4-997)

    • Search Google Scholar
    • Export Citation
  • Kovacs K, Horvath E & Vidal S 2001 Classification of pituitary adenomas. Journal of Neuro-Oncology 54 121127. (https://doi.org/10.1023/a:1012945129981)

    • Search Google Scholar
    • Export Citation
  • Lacerte A, Lee EH, Reynaud R, Canaff L, De Guise C, Devost D, Ali S, Hendy GN & Lebrun JJ 2004 Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. Molecular Endocrinology 18 15581569. (https://doi.org/10.1210/me.2003-0470)

    • Search Google Scholar
    • Export Citation
  • Lebrun JJ 2009 Activin, TGF-beta and menin in pituitary tumorigenesis. Advances in Experimental Medicine and Biology 668 6978. (https://doi.org/10.1007/978-1-4419-1664-8_7)

    • Search Google Scholar
    • Export Citation
  • Lerant A & Freeman ME 1998 Ovarian steroids differentially regulate the expression of PRL-R in neuroendocrine dopaminergic neuron populations: a double label confocal microscopic study. Brain Research 802 141154. (https://doi.org/10.1016/s0006-8993(9800583-6)

    • Search Google Scholar
    • Export Citation
  • Maiter D 2019 Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109 4250. (https://doi.org/10.1159/000495775)

  • Makanji Y, Zhu J, Mishra R, Holmquist C, Wong WPS, Schwartz NB, Mayo KE & Woodruff TK 2014 Inhibin at 90: from discovery to clinical application, a historical review. Endocrine Reviews 35 747794. (https://doi.org/10.1210/er.2014-1003)

    • Search Google Scholar
    • Export Citation
  • Mete O, Cintosun A, Pressman I & Asa SL 2018 Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Modern Pathology 31 900909. (https://doi.org/10.1038/s41379-018-0016-8)

    • Search Google Scholar
    • Export Citation
  • Molitch ME 2017 Diagnosis and treatment of pituitary adenomas: a review. JAMA 317 516524. (https://doi.org/10.1001/jama.2016.19699)

  • Namwanje M & Brown CW 2016 Activins and inhibins: roles in development, physiology, and disease. Cold Spring Harbor Perspectives in Biology 8 a021881. (https://doi.org/10.1101/cshperspect.a021881)

    • Search Google Scholar
    • Export Citation
  • Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, Gahete MD & EYRC (ENEA Young Researcher Committee) 2019 Aggressive and malignant prolactinomas. Neuroendocrinology 109 5769. (https://doi.org/10.1159/000497205)

    • Search Google Scholar
    • Export Citation
  • Piroli GG, Cassataro J, Pietranera L, Grillo CA, Ferrini M, Lux-Lantos V & De Nicola AF 2001 Progestin regulation of galanin and prolactin gene expression in oestrogen-induced pituitary tumours. Journal of Neuroendocrinology 13 302309. (https://doi.org/10.1046/j.1365-2826.2001.00633.x)

    • Search Google Scholar
    • Export Citation
  • Principe M, Chanal M, Karam V, Wierinckx A, Mikaélian I, Gadet R, Auger C, Raverot V, Jouanneau E & Vasiljevic A et al.2018 ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation. Endocrine-Related Cancer 25 795806. (https://doi.org/10.1530/ERC-18-0082)

    • Search Google Scholar
    • Export Citation
  • Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D & Díaz-Torga G 2012 Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology 153 38613871. (https://doi.org/10.1210/en.2012-1007)

    • Search Google Scholar
    • Export Citation
  • Recouvreux MV, Faraoni EY, Camilletti MA, Ratner L, Abeledo-Machado A, Rulli SB & Díaz-Torga G 2018 Sex differences in the pituitary TGFβ1 system: the role of TGFβ1 in prolactinoma development. Frontiers in Neuroendocrinology 50 118122. (https://doi.org/10.1016/j.yfrne.2017.10.003)

    • Search Google Scholar
    • Export Citation
  • Risbridger GP, Schmitt JF & Robertson DM 2001 Activins and inhibins in endocrine and other tumors. Endocrine Reviews 22 836858. (https://doi.org/10.1210/edrv.22.6.0450)

    • Search Google Scholar
    • Export Citation
  • Roberts V, Meunier H, Vaughan J, Rivier J, Rivier C, Vale W & Sawchenko P 1989 Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 124 552554. (https://doi.org/10.1210/endo-124-1-552)

    • Search Google Scholar
    • Export Citation
  • Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M & Huhtaniemi I 2002 Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology 143 40844095. (https://doi.org/10.1210/en.2002-220490)

    • Search Google Scholar
    • Export Citation
  • Sarkar DK 2006 Genesis of prolactinomas: studies using estrogen-treated animals. Frontiers of Hormone Research 35 3249. (https://doi.org/10.1159/000094307)

    • Search Google Scholar
    • Export Citation
  • Suszko MI & & Woodruff TK 2006 Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability. Journal of Molecular Endocrinology 36 591600. (https://doi.org/10.1677/jme.1.01936)

    • Search Google Scholar
    • Export Citation
  • Szeto DP, Ryan AK, O’Connell SM & Rosenfeld MG 1996 P-OTX: a PIT-1-interacting homeodomain factor expressed during anterior pituitary gland development. PNAS 93 77067710. (https://doi.org/10.1073/pnas.93.15.7706)

    • Search Google Scholar
    • Export Citation
  • Thompson TB, Lerch TF, Cook RW, Woodruff TK & Jardetzky TS 2005 The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Developmental Cell 9 535543. (https://doi.org/10.1016/j.devcel.2005.09.008)

    • Search Google Scholar
    • Export Citation
  • Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D & Spiess J 1986 Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321 776779. (https://doi.org/10.1038/321776a0)

    • Search Google Scholar
    • Export Citation
  • Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T & Gatta B et al.2012 Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology 167 651662. (https://doi.org/10.1530/EJE-12-0236)

    • Search Google Scholar
    • Export Citation
  • Welt C, Sidis Y, Keutmann H & Schneyer A 2002 Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Experimental Biology and Medicine 227 724752. (https://doi.org/10.1177/153537020222700905)

    • Search Google Scholar
    • Export Citation
  • Wong A, Eloy JA, Couldwell WT & Liu JK 2015 Update on prolactinomas. Part 2: Treatment and management strategies. Journal of Clinical Neuroscience 22 15681574. (https://doi.org/10.1016/j.jocn.2015.03.059)

    • Search Google Scholar
    • Export Citation